Secondary mitral regurgitation (SMR) is common in patients with heart failure (HF). Although randomized clinical trials have been focused on the treatment of severe SMR, the prognostic role and potential for treatment of moderate SMR cannot be overlooked. The randomized RESHAPE-HF2 trial included patients with moderate and severe SMR with consistent findings in both groups, raising the hypothesis that transcatheter correction of moderate SMR could have beneficial effects though this needs further investigation. The aim of this review is to describe the prevalence of moderate SMR in the patients with HF, its prognostic impact, and discuss current evidence for pharmacological and interventional management of patients with moderate SMR.
EditorsEditor-in-ChiefHarlan M. Krumholz, MD, SM, FACC CME EditorRagavendra R. Baliga, MDAuthorRavi Thakker, MD
Important DatesDate of Release: September 8, 2025Term of Approval/Date of CME/MOC Expiration: September 7, 2026